Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Avelumab + Binimetinib + Liposomal Doxorubicin
- Development stage
- Unknown
- Lead developer
- Merck KGaA
- Modality
- Vaccines & Immunotherapeutics, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Administration
- Oral, Intravenous
01
Overview
Avelumab + Binimetinib + Liposomal Doxorubicin is a combination therapy currently being investigated in a Phase II clinical trial (TBCRC 047: InCITe) for the treatment of metastatic triple-negative breast cancer (TNBC). This therapy combines three distinct drugs: avelumab, an immunotherapy checkpoint inhibitor; binimetinib, a targeted therapy that blocks enzymes needed for cell growth; and liposomal doxorubicin, a chemotherapy drug delivered in tiny fat-like particles.
02
Targets
CD274 (Programmed cell death protein 1 ligand 1)MEK2 (Dual specificity mitogen-activated protein kinase kinase 2)TOP2A (DNA topoisomerase II)FcγR (Low affinity immunoglobulin gamma Fc region receptor II-c)DNAMEK1 (Dual specificity mitogen-activated protein kinase kinase 1)
Beyond the preview
Go deeper on Avelumab + Binimetinib + Liposomal Doxorubicin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Avelumab + Binimetinib + Liposomal Doxorubicin.